The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Sarepta Therapeutics Inc shares valued at $6,296,029 were sold by Brown Ryan Edward on Jun 25 ’24. At $161.61 per share, Brown Ryan Edward sold 38,957 shares. The insider’s holdings dropped to 17,129 shares worth approximately $2.28 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Arif Bilal sold 7,859 shares, netting a total of over 1,281,621 in proceeds. Following the sale of shares at $163.08 each, the insider now holds 21,261 shares.
Before that, Arif Bilal had sold 3,898 shares from its account. In a trade valued at $636,271, the Chief Tech Ops Officer traded Sarepta Therapeutics Inc shares for $163.23 each. Upon closing the transaction, the insider’s holdings decreased to 3,898 shares, worth approximately $2.31 million.
As published in a research note from RBC Capital Mkts on July 29, 2024, Sarepta Therapeutics Inc [SRPT] has been rated up from a Sector perform to an Outperform and the price target has been revised to $182. Analysts at Citigroup downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in late June. As of May 31, 2024, Piper Sandler has initiated its “an Overweight” rating for SRPT. Earlier on May 28, 2024, RBC Capital Mkts downgraded its rating. Their new recommendation was “a Sector perform” for SRPT stock which previously was a “an Outperform”.
Analyzing SRPT Stock Performance
During the last five days, there has been a drop of approximately -4.98%. Over the course of the year, Sarepta Therapeutics Inc shares have jumped approximately 38.01%. Shares of the company reached a 52-week high of $173.25 on 06/21/24 and a 52-week low of $91.34 on 01/05/24. A 50-day SMA is recorded $140.92, while a 200-day SMA reached $120.12. Nevertheless, trading volume fell to 1.07 million shares from 1.36 million shares the previous day.
Support And Resistance Levels for Sarepta Therapeutics Inc (SRPT)
According to the 24-hour chart, there is a support level at 130.94, which, if violated, would cause prices to drop to 128.81. In the upper region, resistance lies at 134.49. The next price resistance is at 135.91. RSI (Relative Strength Index) is 40.62 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -7.13, which suggests the price will decrease in the coming days. Percent R is at 64.49%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
